Sequence-specific transcriptional regulators function by stably binding cognate DNA sequences followed by recruitment of both general and specialized factors to target gene promoters. The tumor suppressor p53 mediates its antioncogenic effect on cells by functioning as a sequencespecific regulator. p53 employs a secondary mechanism to suppress tumor formation by permeabilizing the outer mitochondrial membrane, thereby releasing pro-apoptotic factors. Here, we report a potential third biological function of p53: as a transcriptional elongation factor. Using chromatin immunoprecipitation, we demonstrate that human p53 robustly associates with RNA polymerase II (Pol II), but neither Pol I-nor Pol III-transcribed regions in the budding yeast, Saccharomyces cerevisiae. p53's association with open reading frames is mediated by its physical interaction with elongating Pol II, with which p53 travels in vivo and co-immunoprecipitates in vitro. When similarly expressed, the potent acidic activator VP16 cannot be crosslinked to Pol II coding regions. p53 levels comparable to those found in induced mammalian cells confer synthetic sickness or lethality in combination with deletions in genes encoding transcription elongation factors; p53 likewise confers hypersensitivity to the anti-elongation drug 6-azauracil. Collectively, our results indicate that p53 can physically interact with the transcription elongation complex and influence transcription elongation, and open up new avenues of investigation in mammalian cells.
Introduction
The tumor suppressor p53 is a sequence-specific transcription factor that is activated in response to various cellular and genotoxic stresses, and stimulates the expression of genes that induce either cell cycle arrest or apoptosis (Vogelstein et al., 2000) . Its importance in preventing malignancy is indicated by the fact that 50% of analysed human tumors bear mutations in p53, with 97% mapping to p53's core DNA-binding domain (Cho et al., 1994) . Following binding to specific DNA sequences, termed p53 response elements (PREs), p53 transactivates downstream promoters by recruiting general initiation factors, Mediator, histone acetyl transferases, chromatin remodeling enzymes and elongation factors (reviewed in Laptenko and Prives, 2006) . At p53 target genes, the order of factor recruitment, as well as the precise factors recruited, varies depending on the nature of the stress (Espinosa et al., 2003; Gomes et al., 2006; Donner et al., 2007; Mattia et al., 2007) . In addition to its role as an activator, p53 can act as a sequence-specific transcriptional repressor of anti-apoptotic genes as well as of tissue-specific genes (reviewed in Ho and Benchimol, 2003) . p53 also has a novel cytoplasmic function, where in response to DNA damage and hypoxia, it induces outer mitochondrial membrane permeabilization and release of apoptotic activator proteins, leading to cell death (Mihara et al., 2003; Chipuk et al., 2004) .
A sequence-specific activator typically regulates transcription at discrete steps in the transcriptional cascade. These include the local opening of chromatin, recruitment of RNA polymerase II (Pol II) and other components of the general transcription machinery to a gene's promoter, initiation of mRNA synthesis, promoter escape and elongation. Current models suggest that the DNA-bound, immobilized activator catalyses each step via its ability to recruit, directly or indirectly, dedicated factors and enzymes to the local gene region. By contrast, transcriptional elongation factors neither bind DNA nor do they function in a gene-specific fashion. Rather, they are locally recruited-largely but not exclusively by the sequence-specific activator-and tend to travel with elongating Pol II, modulating its activity (reviewed in Sims et al., 2004) .
The nature of the activation domain of the genespecific regulator may dictate whether initiation or elongation is stimulated. The activation domains of human HSF1, E2F1 and VP16, fused to a heterologous DNA-binding domain, stimulate both initiation and elongation, whereas Sp1, CTF and a synthetic activator, AH (amphipathic alpha helix), stimulate only initiation (Blau et al., 1996; Brown et al., 1998) . By contrast, Drosophila HSF primarily regulates elongation, triggering release of paused RNA polymerase (reviewed in Lis and Wu, 1993) . Interestingly, the p53 activation domain stimulates efficient elongation (Blau et al., 1996) and this correlates with its ability to tightly bind TFIIH via the p62 subunit (Xiao et al., 1994; Di Lello et al., 2006) . Together with its ability to recruit general initiation factors such as TBP (TATA-binding protein), TFIIB and Taf1 (Espinosa et al., 2003) , these observations suggest that p53, functioning as a conventional sequence-specific activator, can regulate both transcription initiation and elongation.
We have used the budding yeast, Saccharomyces cerevisiae, to study mechanisms by which p53 binds its target genes and regulates transcription. Yeast is not only amenable to classical and molecular genetic analysis, fundamental concepts in transcription and chromatin have arisen from its use as a model system (see Hampsey, 1998) , including insights into the properties of mammalian transcription factors (reviewed in Kennedy, 2002) . Although lacking a p53 orthologue, yeast has proven fertile ground for the study of this tumor suppressor. p53's role as a gene-specific activator, elucidation of its DNA recognition elements, the dominant-negative nature of oncogenic missense mutants, identification of the two activator subdomains (TA1 and TA2), the role of ING proteins as corepressors and co-activators and targets of its N-terminal activation domain all were elucidated using yeast as a model (Fields and Jang, 1990; Kern et al., 1992; Thukral et al., 1995; Candau et al., 1997; Nourani et al., 2003; Di Lello et al., 2006) .
Here we provide surprising evidence that when expressed in S. cerevisiae, p53 robustly associates with the coding regions of Pol II-(but neither Pol I-nor Pol III-) transcribed genes. p53's binding to coding region chromatin is driven not by the presence of cryptic PREs, but is due to its ability to bind, directly or indirectly, elongating Pol II, with which it co-migrates. Yeast cells expressing p53 are hypersensitive to drugs and mutations that impinge upon transcription elongation, suggesting that p53's interaction with elongating Pol II impedes its activity. Indicative of a p53 role in elongation is its efficient association with elongating Pol II in open reading frames (ORFs), but not in promoters, of active genes. Taken together, our findings provide evidence for a novel nuclear activity of p53, one that greatly expands its potential for regulating gene expression.
Results

p53 associates with the coding regions of genes it transcriptionally activates
To investigate p53's transcriptional mechanisms in a simplified in vivo setting, we introduced the human TP53 gene into S. cerevisiae as its complementary DNA, either on an episome or integrated within the genome, and modulated its expression behind a galactose-inducible promoter. We also constructed a p53-responsive reporter gene by chromosomally integrating two high-affinity PREs in place of the natural heat-shock-responsive enhancer of HSP82. The HSP82 promoter region has an intrinsically high affinity for histones Venturi et al., 2000; Zhao et al., 2005) and in the absence of ectopic p53, the PREs are assembled into a stably positioned nucleosome (schematically depicted in Figure 1b ) and transcription of p53-hsp82 is virtually undetectable (Supplementary Figure 1) .
When p53 expression was induced in a P GAL1 -p53 strain by the addition of galactose, its intracellular levels substantially increased (Figure 1a) , resembling the fold accumulation seen in human cells in response to DNA damage (Espinosa et al., 2003; see also Figure 4d below) . Under these conditions, the p53-responsive reporter was robustly activated, with a transcriptional output comparable to heat-shock-induced HSP82 þ ( Figure 1b , compare lanes 5 and 7). This observation implies that ectopically expressed p53 can recognize and efficiently bind nucleosome-embedded PREs. To demonstrate this more directly, we employed chromatin immunoprecipitation (ChIP) using the p53-specific monoclonal antibody DO-1. As illustrated in Figure 1c , this assay confirmed that p53 efficiently bound the p53-hsp82 promoter concomitant with its activation. Unexpectedly, it also revealed that the ORF and 3 0 -UTR were similarly occupied by p53, despite an absence of any DNA sequence homologous to the consensus PRE (defined in el- Deiry et al., 1992; Wei et al., 2006) . These results reflect authentic p53 association with the gene's coding region and do not arise from p53 bound at the promoter since (1) the mean size of chromatin fragments obtained following sonication, B0.5 kb, was too small for promoter-localized p53 to significantly contribute to immunoprecipitation of ORF-or 3 0 -UTR-containing fragments (1.3 and 1.9 kb distant, respectively) and (2) p53 association at the gene's ORF and 3 0 -UTR actually exceeds its occupancy of the promoter at later time points (quantified in Figure 1d ). In important contrast, p53 shows only background association with the inactive PHO5 promoter (Figure 1c , odd IP lanes). To rule out the possibility of a fortuitous cross-reaction, we tested monoclonal antibodies of different specificity (1801) or origin (DO-1; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA), as well as a polyclonal p53 antiserum, in parallel ChIP assays. As shown in Supplementary Figure 2 , virtually identical results were obtained with these antibodies, thereby arguing for a bona fide p53 coding region interaction.
To test whether p53 association with the hsp82 coding region was unique to this locus or was more generally a characteristic of p53-activated genes, we examined p53 association with two other p53-regulated reporters, one chromosomal (YAR1; see map in Figure 2a ) and the other episomal (p53-his3). As observed above, p53 binding was detected not only at the promoter but also within the coding region (Figure 2a ; data not shown). Thus, at three genes under p53 transcriptional control, the protein not only associated with their promoters, as expected, but also with their linked coding regions. Figure 1 p53 robustly transactivates the integrated p53-hsp82 reporter and binds both its promoter and coding regions. (a) Western analysis. p53 was expressed from an episomal P GAL1 -p53 gene in cells pregrown in 2% raffinose (0 min) to which galactose was added to a final concentration of 2% for the indicated times. Lane 1, cells transformed with vector alone (pRS316). p53 levels were internally normalized to those of Pgk1, with vector alone arbitrarily assigned 1.0. Similar results have been obtained with a strain bearing a chromosomally integrated P GAL1 -p53 allele (see Figure 4a , lanes 5-8). (b) Northern analysis. The p53-hsp82 strain SY1000 was subjected to galactose induction for the times indicated (lanes 1-5); an isogenic HSP82 þ strain was either maintained under non-heatshock conditions (NHS; 30 1C) or subjected to a 20 min heat shock at 39 1C (HS). HSP82 transcript levels, detected by PhosphorImager, were internally normalized to those of SCR1. A physical map of the YAR1-p53-hsp82 locus is provided, showing the locations of the integrated synthetic PREs and sequence-positioned nucleosomes. The dyads of the two nucleosomes map to coordinates À95 and À250, respectively (relative to the ATG of p53-hsp82), as deduced from micrococcal nuclease genomic footprinting (AM Erkine and DSG, unpublished observations). (c) In vivo crosslinking analysis. Top, physical map of p53-hsp82 and location of amplicons whose midpoint coordinates are provided. Bottom, electrophoretic analysis of multiplex 32 P-labelled PCRs using as template input and immunoprecipitated DNA purified from chromatin isolated from strain SY1000. Cells were galactose-induced for the times indicated. þ , chromatin immunoprecipitated with monoclonal antibody DO-1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); À, mock IP. Input, isolated from chromatin sample used for IP in lanes 12, 13. Note that the lane-to-lane variation in PHO5 reflects differences in IP efficiency and DNA recovery, and has not proven reproducible. (d) Summary of p53 ChIP assays (means±s.d.; two independent experiments). Abundance of p53 at the indicated loci is provided relative to its abundance at the inactive PHO5 promoter. Similar results were obtained when ARS504 was employed as an internal load control. (e) TBP occupancy of p53-hsp82. ChIP assay of 120 min galactose-induced SY1000 cells, conducted as above except that a TBP-specific antibody was used (depicted are means ± s.e.m.; N ¼ 3). Abundance of TBP at each region (determined as in (c)) is presented relative to its abundance at ARS504. *T, TATA box. To demonstrate that this behavior can be distinguished from that of TBP, a core promoter-binding factor, we assayed TBP occupancy of the p53-hsp82 gene under activating conditions. As shown in Figure 1e , TBP preferentially cross-linked to the gene's promoter, being virtually undetectable within its ORF. While above-background levels of TBP were detected at an amplicon centered at þ 2000 (coincident with the gene's 3 0 -UTR), this likely reflects TBP occupancy of the constitutive CIN2 core promoter located only 200 bp downstream. Thus, TBP binds the core promoter of activated p53-hsp82, and not to its coding region, underscoring the novelty of p53's behavior.
The correlation between p53 occupancy of p53-hsp82 and YAR1 and their expression raised the possibility that transcription keys p53's association with gene coding regions. To examine this relationship further, we measured Pol II occupancy within the p53-hsp82 and YAR1 coding regions through use of an antibody specific to the Pol II C-terminal domain (CTD). As shown in Figure 2 , Pol II abundance progressively increases within the coding region of each gene in response to galactose, consistent with northern analysis and paralleling p53 occupancy.
p53 associates with heterologous Pol II coding regions and the extent of p53 association correlates with transcription We next tested whether a gene needed to be under p53 transcriptional control in order for the factor to 
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Figure 2 p53 occupies the coding regions of two genes that it transcriptionally activates, mirroring both the location and abundance of Pol II. (a) Physical map of the YAR1-p53-hsp82 locus and a diagrammatic summary of p53 abundance at the indicated loci obtained from ChIP analysis of strain SY1000 using mAb DO-1 as in Figure 1c . Depicted are means ± s.d.; N ¼ 2. (b) Pol II ChIP analysis of the YAR1-p53-hsp82 locus using an anti-CTD antibody. Pol II abundance was calculated based on the net signal of each test locus (immune minus preimmune) normalized to RDN18 (immune minus gel background). Depicted are means±s.d.; N ¼ 2.
p53 co-traverses with elongating RNA polymerase II in vivo SK Balakrishnan and DS Gross associate with its coding region. If the p53-PRE interaction is obligatory for triggering its association with coding regions, then it would be anticipated that p53 would not associate with a gene under the regulation of a heterologous activator. However, as shown in Figures 3a and b , p53 robustly associates with the coding regions of heterologous genes, including both constitutively active (ACT1 and PMA1) and inducible (GAL10). These observations rule out a requirement for p53 itself as the promoter-specific activator. Notably, p53 association with the coding regions of ACT1 and PMA1 is significant even in cells grown in 2% raffinose (0 min), a condition permissive to low levels of p53 expression (see Figure 1a , lane 2 and Figure 4a , lane 5). This indicates that the extent of p53 occupancy is dictated by the transcriptional activity of the gene rather than by the intracellular level of p53 (this issue is further explored below). p53 association with the galactoseinducible GAL10 gene parallels its transcriptional output and mirrors p53 association with p53-hsp82. Given its robust association with actively transcribed Pol II genes, it was of interest to determine whether p53 could also associate with genes transcribed by Pol I and Pol III. It might be expected that if p53 binding reflected a common feature of active chromatin-such as nucleosomal depletion (Dammann et al., 1993; Schwabish and Struhl, 2004; Zhao et al., 2005) -then its association with structural and regulatory RNA genes would be as robust as with protein-encoding ones. However, p53 showed no tendency to associate with actively transcribed Pol III loci (Figure 3c) , despite their prolific level of expression (for example, SCR1, Figure 1b ). p53's association with the Pol I-transcribed RDN18 genes, present in 100-200 tandem repeats, was also low (Figure 3d) . Importantly, the inability to cross-link p53 to either Pol I or Pol III coding regions does not arise from an inherent feature of the chromatin packaging of these genes. Histone H4 can be readily cross-linked to active Pol I and Pol III genes, and at a level comparable to active Pol II genes (data not shown). Therefore, nucleosomal disassembly is unlikely to contribute to p53's specific association with Pol II-transcribed genes.
We next asked whether p53's unexpected association with Pol II coding regions was a consequence of cellular stress, triggered by a shift in carbon source. Profound changes in genome-wide transcription take place in response to various cellular stresses in yeast (Gasch et al., 2000) , and we thought it possible that this may contribute to p53's unusual behavior. To rule this out, we constructed a strain in which the TP53 ORF was regulated by the constitutive ADH1 promoter, permitting ectopic expression of p53 in cells grown in glucose (Figure 4a, lane 4) . Paralleling findings with the galactose-induced P GAL1 -p53 strains, significant association of p53 was observed within the coding regions of both ACT1 and PMA1, while essentially at background levels at Pol III-transcribed SCR1 (Figure 4b ). Therefore, p53 specifically and selectively associates with active Pol II genes irrespective of growth conditions or its mode of expression.
The potent mammalian activator, VP16, does not associate with transcribed regions in vivo To test whether p53's association with active transcribed regions is a general characteristic of potent mammalian activators, we ectopically expressed the herpes simplex viral activator VP16 fused to a heterologous DNAbinding domain. Although stably expressed (data not shown), the LexA-VP16 fusion protein shows no p53 co-traverses with elongating RNA polymerase II in vivo SK Balakrishnan and DS Gross tendency to associate with actively transcribed coding regions (Figure 4c ). It does, however, bind efficiently to a promoter bearing LexA response elements (Supplementary Figure 3) . Taken together with a failure of >10-fold overexpressed yeast HSF to associate with coding regions (Supplementary Figure 4) , these findings further establish the novelty of p53's behavior.
p53 expression in S. cerevisiae is comparable to that observed in human cells Despite our earlier demonstration that p53 occupancy of Pol II coding regions is substantial even when p53 expression is low (2% raffinose conditions; see Figures 3a and b; 0 min time points), it is possible that even this low level represents an overexpressed state compared to typical intracellular concentrations found in induced mammalian cells. To rule this out, we compared the p53 level in glucose-grown yeast cells (harboring an episomal P ADH1 -p53 gene) with hydroxyurea (HU)-induced HCT116 human colon carcinoma cells. As can be seen in Figure 4d , the level of p53 in yeast cells, normalized to total cellular protein, is comparable to that seen in 24 hinduced HCT116 cells. Given that this level is >5-fold higher than found in P GAL1 -p53 cells cultivated in 2% raffinose (Figure 4a , compare lanes 4 and 5), p53's 
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Figure 4 p53 association with active coding regions in S. cerevisiae does not stem from cellular stress, a general property of mammalian activators, or non-physiological levels of p53 expression. (a) Western analysis illustrating p53 expression levels in cells constitutively expressing p53 (S288C-p53 cells grown in 0.2% galactose/1.8% raffinose (lane 3) or YYO2-P ADH1 -p53 cells grown in 2% glucose (lane 4)) and those inducibly expressing p53 (strain SY1000, bearing an integrated P GAL1 -p53 gene, pre-grown in 2% raffinose) over the indicated time course in 2% galactose (lanes 5-8). Lanes 1, 2, vector alone controls. (b) p53 occupancy of ACT1, PMA1 and SCR1 in the P ADH1 -p53 strain YYO2-ADH1 grown in 2% glucose. Depicted are means±s.d. (N ¼ 2) . (c) VP16, unlike p53, exhibits no tendency to associate with active coding regions. ChIP analysis of p53 and LexA-VP16 association with the indicated regions of the constitutively transcribed ACT1 and PMA1 genes in strain YYO2 (means ± s.d.; N ¼ 2). (d) p53 is expressed in yeast at levels that approximate those in human cells. p53 immunoblot analysis of 60 mg WCE isolated from HCT116 cells treated with 1.7 mM HU for 0, 16 or 24 h (lanes 1-3) and 20 mg WCE isolated from P ADH1 -p53-transformed YYO2 cells (lane 4) using the DO-1 mAb. When normalized for load, 24 h-induced HCT116 cells express 0.75 units p53 per mg WCE, while YYO2 cells express 1.5 units p53 per mg WCE.
p53 co-traverses with elongating RNA polymerase II in vivo SK Balakrishnan and DS Gross coding region association is unlikely to be a consequence of its overexpression.
p53 co-traverses with the transcription elongation complex and physically associates with RNA Pol II To address the possibility that p53 travels with elongating Pol II, we exploited the dynamic transcriptional response of heat-shock genes, whose mRNA levels both increase and decrease rapidly in response to environmental cues (see for example, Lee and Gross, 1993) . Indeed, in control (p53 À ) cells exposed to a brief 39 1C heat shock followed by an instantaneous 23 1C downshift, Pol II levels diminish within the 5 0 ends of the HSP82 and HSP104 genes, and this is evident within 30 s (Figures 5a and b; top panels, diamonds) . At the same time, a surge in Pol II abundance can be seen within both the middle and 3 0 ends of these genes (squares and triangles, respectively), peaking at 30 s and apparently representing the last major wave of transcription. This wave passes shortly thereafter, and in its wake are background levels of Pol II (5 min time points). Similar, although not identical, kinetics of Pol II occupancy are seen in p53 þ cells (Figures 5a and b , bottom left panels). Importantly, in the latter cells, the kinetics of p53 occupancy at the 5 0 -, mid-and 3 0 -locations of each gene closely parallel those of Pol II (Figures 5a and b, bottom right panels) . In particular, p53 abundance at each 5 0 -end diminishes following shift to the lower temperature, while transiently surging over the ORF and 3 0 ends. The surge in Pol II levels within mid-and 3 0 -ORF regions of these genes in response to À or p53 þ (P GAL1 -p53) cells that were chronically grown in 1.8% raffinose/0.2% galactose using monoclonal antibodies specific to Myc or p53 as indicated. These were evaluated for the presence of either Pol II (Rpb1) or p53 by immunoblot analysis as indicated (lanes 1-4) . WCEs from p53 À and p53 þ cell extracts using either preimmune or anti-Pol II antiserum, and these, along with WCEs as in panel c, were evaluated for the presence of p53. IgG, heavy chain of rabbit IgG. (e) Pol IIo Ser5 co-IPs with p53. IPs were conducted as in panel c, and samples were evaluated for the presence of Ser5-phosphorylated Rpb1 using mAb H14.
p53 co-traverses with elongating RNA polymerase II in vivo SK Balakrishnan and DS Gross thermal downshift was unanticipated; nonetheless, p53 occupancy mirrors that of Pol II, suggesting that p53 tracks with elongating Pol II.
To show more directly that p53 physically associates with elongating RNA polymerase, we asked whether Pol II and p53 co-immunoprecipitate from whole cell extracts (WCEs). As shown in Figure 5c , Rpb1, the largest subunit of Pol II, is readily detected in a p53 immunoprecipitate generated from WCEs of p53 þ , but not p53 À , cells (lanes 4 vs 2) . Likewise, p53 is abundant in the Rpb1 immunoprecipitate generated from p53 þ cells using a polyclonal anti-CTD antiserum, but not in one generated by preimmune serum (Figure 5d, lanes 4  vs 3) . As a control, we asked whether HSF likewise copurified with Pol II. It did not (data not shown). Interestingly, the Ser5-phosphorylated isoform of p53 (Pol IIo Ser5 ), characteristic of polymerase that has initiated transcription and is unable to assemble into the pre-initiation complex (Sims et al., 2004) , is also detectable in the p53 immunoprecipitate, but not in one generated by an antibody specific to an unrelated epitope ( Figure 5e, lanes 4 vs 3) . Taken together with the kinetic ChIP assays, these results indicate that p53 physically associates with transcriptionally competent Pol II, both in vivo and in vitro. þ cells exhibit striking synthetic elongation phenotypes The foregoing experiments suggest that p53 associates with Pol II coding regions and travels with elongating Pol II. We sought genetic evidence that p53 acts, at least in part, to modulate elongation. To do so, we asked whether p53-expressing cells exhibit elevated sensitivity to 6-azauracil (6-AU). Exposure of cells to 6-AU leads to a reduction in both Pol II elongation rate and processivity (Mason and Struhl, 2005) , secondary to the depletion of cellular UTP and GTP pools (Exinger and Lacroute, 1992) . If p53 significantly impedes Pol II elongation (at least at one essential gene), its presence in combination with low concentrations of 6-AU would be expected to elicit synthetic sickness or lethality. Indeed, p53 þ S288C cells exhibit striking sensitivity to 6-AU (Figure 6a, WT þ cells) . Notably, such synthetic lethality occurs under conditions in which p53 intracellular levels are relatively low, since cells were grown in 1.8% raffinose/0.2% galactose (see Figure 4a, lane 3) . p53 þ cells grow nearly as well as their p53 À counterparts on this same medium lacking 6-AU (Figure 6a , 0 mg ml À1 6-AU, compare þ vs Àrows), in accord with the modest effects of p53 alone on the transcriptional output of the ACT1 and PMA1 genes (data not shown). Likewise, p53
À cells retain close to full viability when grown in presence of low concentrations of 6-AU (25 mg ml
À1
). Moreover, 6-AU hypersensitivity is not suppressed by a deletion of PAK1 (Figure 6a) , a gene encoding a kinase that positively regulates p53's promoter function in yeast (Thiagalingam et al., 1995) . This further demonstrates that the global elongation function of p53 is independent of its transactivation function.
We next asked whether p53 genetically interacts with transcriptional elongation factors. If p53 globally impairs Pol II elongation, then its expression in combination with a mutation in a gene encoding an elongation factor might further exacerbate the growth defect. To facilitate detection of synthetic growth phenotypes, we used a strain background (SLY101) less sensitive to the toxic effects of 6-AU than the one employed above. As illustrated in Figure 6b , striking synthetic phenotypes were observed in p53-expressing cells bearing lesions in genes encoding elongation factors of Pol II. Deletion of DST1, ISW1 and SET1-encoding TFIIS, a nucleosome-remodeling enzyme and a histone methyltransferase, respectively-elicits synthetic sickness or lethality with p53 even in the absence of 6-AU. This suggests that the synthetic phenotypes seen in strain S288C are very likely due to elongation defects, and not to pleiotropic effects of either p53 or 6-AU. Particularly notable is the exquisite sensitivity of dst1D cells to the presence of p53. Even when grown in glucose, a condition in which expression of the episomal P GAL1 -p53 gene is very low, the presence of p53 coupled with the absence of TFIIS confers a striking growth phenotype (Figure 6b , 2% glucose, compare þ vs À p53 rows).
In addition to these three elongation factors, deletion of two others-SPT4 and CTK1, encoding a component of the DSIF elongation complex and a Pol II CTD kinase, respectively-are synthetically lethal with p53, but only in the presence of 6-AU (Figure 6b ). p53 did not impair the viability of other elongation factor mutants, including spt16 (encoding an essential subunit of FACT), chd1, isw2 or fkh1, nor did it aggravate their 6-AU sensitivity, while an fkh2D mutation modestly suppressed the p53-induced growth defect (Figures 6a  and b ; data not shown; genetic interactions summarized in Figure 6c ). These genetic data suggest the possibility Figure 6 p53-expressing cells exhibit striking 6-AU phenotypes and synthetic lethality in combination with mutations in elongation factor genes. (a) Fivefold serial dilutions of strain S288C (wild type; WT) and isogenic fkh1D, fkh2D and pak1D mutants (top), or of strain FY120 (WT) and its isogenic spt16-197 counterpart (FY348) (bottom), transformed with either Yp53 (GAL1-p53 CEN6 URA3) or empty vector (pRS316) ( þ and À, respectively), were spotted onto synthetic rich medium containing 1.8% raffinose/0.2% galactose and the indicated 6-AU concentrations. Cells were grown at 30 1C for 4, 7 or 7 days (top left, middle, and right, respectively) or for 5 days (bottom, all three panels). (b) Spot dilution analysis of strain SLY101 (WT) and isogenic spt4D, dst1D, ctk1D, isw1D, isw2D and set1D derivatives. Performed as in panel a, except cells were spotted onto media containing either 2% glucose or 1.8% raffinose/0.2% galactose ± 6-AU as indicated. Cells were grown for 2.5, 4 or 8 days (top left, middle and right, respectively) or for 3, 6 or 9 days (bottom). (c) Synthetic genetic interaction map illustrating genetic interactions of p53 with transcriptional elongation factors as inferred from spot dilution analysis. Green shaded arrows indicate p53 interactions with mutated factors that exacerbate the growth phenotype; the yellow arrow indicates an interaction that alleviates p53-induced lethality of cells grown in the presence of 50 mg ml À1 6-AU. 
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No interaction p53 co-traverses with elongating RNA polymerase II in vivo SK Balakrishnan and DS Gross that p53 can adversely affect elongation, and in combination with the ChIP and co-IP data, imply that p53 does so through a novel mechanism involving its physical interaction with the transcription elongation complex.
Discussion
p53 associates with the coding regions of actively transcribed genes and kinetically mirrors the association of Pol II In this study, we present molecular and genetic evidence indicating that human p53 can behave as a negative transcriptional elongation factor in a model in vivo system. Four lines of evidence demonstrate that p53 physically associates with the Pol II elongation complex. First, p53 associates efficiently with gene coding regions. This association is specific to actively transcribed regions and is selective for Pol II-transcribed loci; p53 inefficiently binds regions transcribed by either Pol I or Pol III, and evinces no binding to nontranscribed loci. Second, p53 association is not a consequence of a particular growth condition, nor is it due to overexpression. Indeed, the extent of p53 association with a coding region is dictated by a gene's transcriptional output, not by intracellular p53 levels. In contrast to p53's behavior, two other transcriptional activators, yeast HSF and mammalian VP16, when similarly overexpressed, evinced no tendency to associate with active coding regions. Thus, despite all three proteins being acidic activators, there exists a fundamental difference in the biology of p53 on the one hand, and HSF and VP16 on the other. In addition, a kinetic analysis of Pol II and p53 occupancy within the transcribed regions of rapidly regulated genes reveals a tight correlation between Pol II occupancy and that of p53. This implies that p53 cotraverses, and therefore physically associates, with elongating Pol II. In agreement, a fourth line of evidence, co-immunoprecipitation, demonstrates that the large Pol II subunit co-purifies with p53 from WCEs. The same is true for the Ser5 phosphorylated isoform of Rpb1 (Pol IIo Ser5 ), indicating that p53 can physically associate with a transcriptionally competent form of RNA polymerase. We attempted to extend this analysis to the Ser2 phosphorylated isoform of Pol II, given its link to later stages of elongation (Komarnitsky et al., 2000) , but were unable to detect Pol IIo Ser2 in our WCEs using the H5 monoclonal antibody. Together, our data argue that p53 physically interacts with a component of the Pol II transcription elongation complex, both in vivo and in vitro.
p53 interacts genetically with factors pivotal to transcriptional elongation To extend the above observations, we performed a genetic analysis of p53's role in Pol II elongation. p53 conferred hypersensitivity to cells exposed to low concentrations of the elongation inhibitor 6-AU. More strikingly, even in the absence of the drug, p53 conferred synthetic sickness when combined with deletions of the elongation factors Isw1 and Set1, and synthetic lethality when combined with deletion of TFIIS. In addition, in the presence of low concentrations of 6-AU, deletions of Spt4 and Ctk1 were synthetically lethal with p53. Deletion of the elongation factor Fkh2, on the other hand, suppresses the toxic effects of p53 in the presence of 6-AU, which may be attributable to less stalling during elongation in the fkh2D strain. Other putative elongation factors showed no genetic interaction with p53, including Fkh1, Isw1, Spt16 and Chd1 (synthetic interactions summarized in Figure 6c ), indicating that p53's effects on Pol II elongation are specific. The suppressing effect of the fkh2D mutation is consistent with the exacerbating effects of deleting TFIIS, Isw1 and Set1. The latter three factors are thought to play important roles during early elongation, when Pol II is most susceptible to stalling (reviewed in Saunders et al., 2006) . Thus, following its binding to the transcription elongation complex, p53 may elicit inappropriate stalling or pausing, thereby reducing Pol II elongation rate, processivity or both.
The p53-Pol II interaction in yeast may represent the 'default' state of a highly regulated interaction in mammalian cells It is tempting to speculate that the activities observed here reflect fundamental biochemical properties of p53 that are evolutionarily conserved. Nonetheless, the behavior has not yet been reported, either at p53 target genes (for example, Espinosa et al., 2003; Kaeser and Iggo, 2004; Gomes et al., 2006; Mattia et al., 2007) or in genome-wide ChIP analyses (Cawley et al., 2004; Wei et al., 2006) . However, it is likely that p53's association with elongating Pol II will be highly regulated, and factors that antagonize the p53-Pol II interaction, although not abundant in yeast (and possibly missing altogether), do exist in mammalian cells. Indeed, at p53-activated genes, a failure to observe p53 occupancy within their transcribed regions is the predicted outcome given that p53's association with elongating Pol II negatively regulates transcription. Thus its presence within activated coding regions would antagonize the activity of p53 bound to the promoters of such genes, and therefore would not be expected.
In this regard, p53 function in elongation may prove to be more analogous to the stress-activated Hog1 kinase of budding yeast-whose association with the transcription elongation complex is induced by high osmolarity and is restricted to specific protein-encoding genes (Pokholok et al., 2006; Proft et al., 2006 )-than to a general transcription elongation factor. It is also worth noting that p53 has been shown to bind, through its C-terminal domain, the mammalian elongation factor ELL (Shinobu et al., 1999) . p53 was shown to inhibit the transcription elongation activity of ELL in vitro, providing an intriguing complement to our in vivo observations. Whatever might prove to be p53's binding partner(s)-which the present experiments do not p53 co-traverses with elongating RNA polymerase II in vivo SK Balakrishnan and DS Gross address-it is likely that such interactions will be highly regulated and gene-specific.
In conclusion, we have shown that in the appropriate in vivo context, p53 can associate with actively transcribing regions and physically bind the elongating Pol II complex in the absence of any other targeting entity. This association appears to influence Pol II elongation, given the striking synthetic growth phenotypes, which result from combining expression of p53 with a targeted mutation in any one of several Pol II elongation factors. Whether p53 alone influences elongation, or whether it acts to recruit additional factors that in turn modulate Pol II elongation, is an intriguing but as yet unanswered question. Either way, p53's ability to physically associate with the transcription elongation complex greatly expands its potential for regulating gene expression, and opens up new avenues of investigation in mammalian systems.
Materials and methods
Procedural details of strain construction, cell cultivation, ChIP, northern analysis, immunoblot assays, immunoprecipitation from WCEs and genetic assays are provided in Supplementary Methods.
